Distinguished in Cushing's syndrome due to Adrenal Tumor

Dr. Eliza Geer

Endocrinology
Memorial Endocrine Group
205 E 64th St, 
New York, NY 
Offers Telehealth
Distinguished in Cushing's syndrome due to Adrenal Tumor
Memorial Endocrine Group
205 E 64th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eliza Geer is an Endocrinologist in New York, New York. Dr. Geer is rated as a Distinguished provider by MediFind in the treatment of Cushing's syndrome due to Adrenal Tumor. Her top areas of expertise are Cushing's disease, Cushing's syndrome, Pituitary Tumor, and Acromegaly.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Cushing's syndrome due to Adrenal Tumor.

Specialties
Endocrinology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Northwell Health
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

MEMORIAL ENDOCRINE GROUP
205 E 64th St, New York, NY 10065

Additional Areas of Focus

Dr. Geer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)
Pediatric Growth Hormone Deficiency

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

69 Total Publications

Consensus on acromegaly therapeutic outcomes: an update.
Consensus on acromegaly therapeutic outcomes: an update.
Journal: Nature reviews. Endocrinology
Published: June 30, 2025
Similar Doctors
Distinguished in Cushing's syndrome due to Adrenal Tumor
Dr. Alice C. Levine
Endocrinology
Distinguished in Cushing's syndrome due to Adrenal Tumor
Dr. Alice C. Levine
Endocrinology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (1.8 miles away)
212-241-7975
Languages Spoken:
English
See accepted insurances

Alice Levine is an Endocrinologist in New York, New York. Dr. Levine is rated as a Distinguished provider by MediFind in the treatment of Cushing's syndrome due to Adrenal Tumor. Her top areas of expertise are Cushing's syndrome, Adrenal Gland Adenoma, Pheochromocytoma, and Ectopic Cushing's syndrome.

Advanced in Cushing's syndrome due to Adrenal Tumor
Dr. Edward Condon
Endocrinology
Advanced in Cushing's syndrome due to Adrenal Tumor
Dr. Edward Condon
Endocrinology

Edward Condon Medical PC

6080 Jericho Tpke, Suite 314, 
Commack, NY 
 (34.9 miles away)
631-462-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Condon is an Endocrinologist in Commack, New York. Dr. Condon is rated as a Distinguished provider by MediFind in the treatment of Cushing's syndrome due to Adrenal Tumor. His top areas of expertise are Hashimoto Thyroiditis, Polycystic Ovary Syndrome, Obesity in Children, and Infertility.

Advanced in Cushing's syndrome due to Adrenal Tumor
Dr. Marcelle Pignanelli
Endocrinology
Advanced in Cushing's syndrome due to Adrenal Tumor
Dr. Marcelle Pignanelli
Endocrinology

Icahn School Of Medicine At Mount Sinai

780 8th Ave, 
New York, NY 
 (1.2 miles away)
212-641-4500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marcelle Pignanelli is an Endocrinologist in New York, New York. Dr. Pignanelli is rated as an Advanced provider by MediFind in the treatment of Cushing's syndrome due to Adrenal Tumor. Her top areas of expertise are Cushing's syndrome, Exogenous Cushing's syndrome, Cushing's syndrome due to Adrenal Tumor, and Polycystic Ovary Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Geer's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 22 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile